Phosphosignature Predicts Dasatinib Response in Non-small Cell Lung Cancer

Targeted drugs are less toxic than traditional chemotherapeutic therapies; however, the proportion of patients that benefit from these drugs is often smaller. A marker that confidently predicts patient response to a specific therapy would allow an individual therapy selection most likely to benefit...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Klammer, Martin, Kaminski, Marc, Zedler, Alexandra, Oppermann, Felix, Blencke, Stephanie, Marx, Sandra, Müller, Stefan, Tebbe, Andreas, Godl, Klaus, Schaab, Christoph
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: The American Society for Biochemistry and Molecular Biology 2012
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3434785/
https://ncbi.nlm.nih.gov/pubmed/22617229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/mcp.M111.016410
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak